The Food and Drug Administration yesterday released recommendations for streamlining the approval process for medical devices that use artificial intelligence. The guidance recommends information to include in a predetermined change control plan as part of a marketing submission for a medical device using AI. The PCCP should include a description of the device's planned modifications; methods to develop, validate and implement the modifications; and an assessment of the modification's impacts. FDA will then review the PCCP within the submission to ensure the device's safety and effectiveness without needing additional marketing submissions for each modification. 

Related News Articles

Headline
Comments are due Oct. 27 to the Office of Science and Technology Policy on federal regulations that hinder artificial intelligence development, deployment or…
Headline
An AHA blog published today shares how HCA Healthcare in Nashville, Tenn., has been leveraging artificial intelligence to reduce risk and improve health…
Blog
Public
Cross-industry insights and new technology are helping HCA Healthcare reduce risk, improve outcomes and lead the future of high-reliability careFor Randy Fagin…
Headline
The AHA discussed ways hospitals and health systems are leveraging artificial intelligence for care delivery in a statement submitted to the Senate…
Headline
The Department of Health and Human Services announced Sept. 30 that it is doubling its funding for childhood cancer research from $50 million to $100 million…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…